Argenx SE Files 2024 Annual Report
Ticker: ARGX · Form: 20-F · Filed: Mar 20, 2025 · CIK: 1697862
| Field | Detail |
|---|---|
| Company | Argenx Se (ARGX) |
| Form Type | 20-F |
| Filed Date | Mar 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, biotech, sec-filing
TL;DR
Argenx SE dropped its 2024 20-F, check financials for biotech giant.
AI Summary
Argenx SE filed its 20-F annual report for the fiscal year ending December 31, 2024. The report details the company's financial performance and business operations. Argenx SE is a biopharmaceutical company focused on developing treatments for autoimmune diseases and cancer.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Argenx SE's financial health and strategic direction for the past year, crucial for understanding its market position and future prospects.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Argenx SE faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (The report covers the financial performance up to this date.)
- 2025-03-20 — Filing Date (The date the 20-F report was submitted to the SEC.)
Key Players & Entities
- ARGENX SE (company) — Filer of the 20-F report
- 2024-12-31 (date) — Fiscal year end date for the report
- 2025-03-20 (date) — Filing date of the report
FAQ
What is the primary business of Argenx SE?
Argenx SE is a biopharmaceutical company focused on developing treatments for autoimmune diseases and cancer.
What period does this 20-F filing cover?
This 20-F filing covers the fiscal year ending December 31, 2024.
When was this 20-F report filed?
This 20-F report was filed on March 20, 2025.
What is the Standard Industrial Classification for Argenx SE?
The Standard Industrial Classification for Argenx SE is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
What is the company's business address?
The company's business address is INDUSTRIEPARK ZWIJNAARDE 7, BUILDING C, B-9052 ZWIJNAARDE, Belgium.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on March 20, 2025 regarding ARGENX SE (ARGX).